Sol-Gel Technologies Ltd.
SLGL Healthcare Biotechnology
Sol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024. In the quarter to June 2026, revenue fell 96.6%, EPS fell 127.1% and free cash flow fell 8.76%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SLGL
Sol-Gel Technologies Ltd. (SLGL) EV/Sales
As of 16 October 2026, Sol-Gel Technologies Ltd. (SLGL) trades at a EV/Sales of 127×. Over the past ten years it has ranged from 0.0× (December 2018) to 1,022× (February 2019); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.2× | 40.31% |
| FY2024 | 5.8× | (87.12%) |
| FY2023 | 45.3× | 14.51% |
| FY2022 | 39.6× | 477.52% |
| FY2021 | 6.8× | (76.67%) |
| FY2020 | 29.4× | 92.18% |
| FY2019 | 15.3× | (98.22%) |
| FY2018 | 860× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 145× | 1,026.96% |
| Mar 2026 | 12.8× | 56.94% |
| Dec 2025 | 8.2× | 23.55% |
| Sep 2025 | 6.6× | 157.14% |
| 30 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QTTB Q32 Bio Inc. compare | −8.3× |
| KROS Keros Therapeutics, Inc. compare | −1.4× |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| PLX Protalix BioTherapeutics, Inc. compare | 2.3× |
| FATE Fate Therapeutics, Inc. compare | 13.1× |
| CAMP CAMP4 Therapeutics Corporation compare | 22.9× |
| SLGL Sol-Gel Technologies Ltd. | 127× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)